AbbVie Submits Regulatory Applications to the US FDA and EMA for Rinvoq (upadacitinib) to Treat Active Ulcerative Colitis
Shots:
- The application is based on 2 P-III U-ACHIEVE & U-ACCOMPLISH induction studies & 1 U-ACHIEVE maintenance study evaluating upadacitinib (45mg- qd) as IT & (15/30 mg- qd) as MT vs PBO in patients with mod. to sev. UC
- The studies met its 1EPs i.e.- patients achieved clinical remission (per Adapted Mayo Score) & 2EPs for induction (45mg) & maintenance studies (15/30 mg) @8 & 52wks. respectively. The safety results were consistent with a known safety profile of upadacitinib & no new safety risks were identified
- Rinvoq (15mg) is approved in the US for RA & in the EU for RA- PsA- AS & AD while 30mg dose is approved in the EU for AD. The P-III trials are ongoing for multiple indications
| Ref: PR Newswire | Image: abbvie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com